A target for tumour-directed therapy.
Hynes
N E
NE
Friedrich Miescher Institute, Basel, Switzerland.
Groner
B
B
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000276:immunology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D015536:Down-Regulation; D015195:Drug Design; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000628:therapy; D008324:Mammary Tumor Virus, Mouse / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000276:immunology*; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000276:immunology
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases